Carlyle Group injects $260M into a leading cardio player in China, grabbing a seat at the deals table
The Carlyle Group is investing $260 million to grab a minority stake in Shenzhen Salubris Pharmaceutical, a storied generic maker that’s increasingly investing in new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.